Inflammatix wins $1.7M NIH grant

By LabPulse.com staff writers

November 15, 2021 -- Inflammatix has won a $1.7 million grant from the U.S. National Institutes of Health (NIH) that it plans to use to develop a rapid diagnostic test that will identify immune subtypes of sepsis.

Using host immune mRNA signatures, the company has identified three sepsis subtypes ("endotypes"). The NIH award will allow Inflammatix to further investigate each endotype's signature and to develop a rapid, 30-minute test to identify them, it said.

Inflammatix secures $102M in financing
Molecular diagnostics firm Inflammatix has secured $102 million in financing that it plans to use to commercialize its novel immune response diagnostics...
Inflammatix secures $7.4M in BARDA funding
Molecular diagnostics firm Inflammatix has secured an additional $7.4 million in funding from the Biomedical Advanced Research and Development Authority...
Inflammatix gets $32M infusion for HostDx rapid POC tests
California startup Inflammatix has raised $32 million in series C financing, which it plans to use to move its HostDx rapid point-of-care (POC) tests...
Inflammatix scores BARDA contract for infection tests
Startup Inflammatix is set to get $6 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) and up to $72 million...
AACC: Inflammatix sepsis test wins Disruptive Technology contest
ANAHEIM, CA - A blood test for sepsis developed by California startup Inflammatix beat out products from two other companies to win the Disruptive Technology...

Copyright © 2021 LabPulse.com

Last Updated ls 11/15/2021 5:28:39 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current